Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX:APLI, OTC:APLIF) ("Appili"), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats.
Aditxt, Inc. ("Aditxt"或"公司") (NASDAQ:ADTX)，一家致力于发现、开发和部署有前景的健康创新的创新平台，今天宣布与Appili Therapeutics, Inc. (TSX:APLI，OTC:APLIF) ("Appili")签订了第三份修订协议，Appili是一家专注于开发创新治疗方法和疫苗以应对一些具有挑战性的传染性疾病和潜在生物恐怖主义威胁的生物制药公司。
Under the terms of the Arrangement Agreement announced on April 2, 2024, Aditxt, through its wholly-owned subsidiary Adivir, Inc., agreed to acquire all outstanding Class A common shares of Appili. Under the third amending agreement, the Arrangement Agreement was amended to, inter alia: (i) change the Outside Date (as defined in the Arrangement Agreement) from September 30, 2024 to November 19, 2024; (ii) require Appili to convene an annual and special shareholder's meeting of Appili to consider, among other things, the Continuance (as defined below) as promptly as practicable; (iii) change the deadline to convene a special shareholders' meeting to consider the Transaction from September 30, 2024 to November 6, 2024; (iv) change the deadline for Aditxt to complete the Financing (as defined in the Arrangement Agreement) from September 15, 2024 to October 18, 2024; and (v) have the completion of the Continuance as a condition to the completion of the Arrangement.
根据2024年4月2日宣布的协议的条款，Aditxt通过其全资子公司Adivir, Inc.同意收购Appili的所有未上市A类普通股。根据第三份修订协议，该协议被修订为：（i）将外界日期（在该协议中定义）从2024年9月30日更改为2024年11月19日；（ii）要求Appili召集Appili的年度股东大会和特别股东大会，以尽快考虑继续进行（如下所定义）；（iii）将召集特别股东大会考虑交易的截止日期从2024年9月30日更改为2024年11月6日；（iv）将Aditxt完成融资（在该协议中定义）的截止日期从2024年9月15日更改为2024年10月18日；以及（v）将继续完成作为完成交易的条件。
The transaction is conditional upon Aditxt raising at least US$20 million in financing before closing. In addition, completion of the transaction is subject to other customary conditions, including the receipt of all necessary court, regulatory, and stock exchange approvals. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.
交易的条件是Aditxt在交易完成前至少筹集2000万美元的融资。此外，交易完成还需要满足其他常规条件，包括获得所有必要的法院、监管和股票交易所的批准。不能保证所有的交易完成条件都能获得或满足，也不能保证最终能够完成交易。
